# Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

> **NCT02533570** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 20 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02533570
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533570, "Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02533570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*